Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: J Urol. 2020 Jan 23;204(1):63–70. doi: 10.1097/JU.0000000000000761

Figure 3:

Figure 3:

Progression free survival (PFS) after initiating ICI among patients with tumors containing neuroendocrine features compared to patients with PUC or VUC.

PFS analysis of patients with aUC receiving ICI, with Kaplan-Meier curve depicting PFS among patients with PUC (n= 284, solid line), VUC excluding NE (n= 110, dotted line) or tumors with NE features (n= 9, dashed line). Median PFS was 4.1 months for patients with PUC, 5.2 months for patients with VUC excluding NE, and 3.7 months for patients with NE features (HR 2.24 compared to VUC without NE, 95%CI 1.07 - 4.69, p = 0.03).